Misplaced Pages

MRTX1133

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
MRTX1133
Clinical data
Drug classAntineoplastic agents
ATC code
Identifiers
IUPAC name
  • 4-(4-(3,8-Diazabicyclooctan-3-yl)-8-fluoro-2-(((2R,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methoxy)pyridopyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
PDB ligand
Chemical and physical data
FormulaC33H31F3N6O2
Molar mass600.646 g·mol
3D model (JSmol)
SMILES
  • C#CC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC78CCCN7C(C8)F)O)F
InChI
  • InChI=InChI=1S/C33H31F3N6O2/c1-2-23-26(35)7-4-18-10-22(43)11-24(27(18)23)29-28(36)30-25(13-37-29)31(41-15-20-5-6-21(16-41)38-20)40-32(39-30)44-17-33-8-3-9-42(33)14-19(34)12-33/h1,4,7,10-11,13,19-21,38,43H,3,5-6,8-9,12,14-17H2/t19-,20?,21?,33+/m1/s1
  • Key:SCLLZBIBSFTLIN-IFMUVJFISA-N

MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. It is currently in a phase 1/2 clinical trial for the treatment of solid tumors. MRTX1133 is considered to be harmful from direct skin or eye exposure other than transient irritation. It may cause irritation of the respiratory system if inhaled.

See also

References

  1. "MRTX 1133". AdisInsight. Springer Nature Switzerland AG.
  2. Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD (November 2023). "Next batter up! Targeting cancers with KRAS-G12D mutations". Trends in Cancer. 9 (11): 955–967. doi:10.1016/j.trecan.2023.07.010. PMID 37591766.
  3. Clinical trial number NCT05737706 for "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation" at ClinicalTrials.gov
  4. "MRTX1133 Safety Data Sheet". TargetMol. Retrieved 11 September 2024.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: